NCT00040170

Brief Summary

This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_2

Geographic Reach
1 country

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2002

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 21, 2002

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 25, 2002

Completed
Last Updated

November 2, 2006

Status Verified

October 1, 2006

First QC Date

June 21, 2002

Last Update Submit

October 31, 2006

Conditions

Prostatic Neoplasms

Keywords

Adenocarcinoma of the prostate

Interventions

MVA-MUC1-IL2BIOLOGICAL

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Rising PSA after surgery or radiation for prostate cancer

You may not qualify if:

  • Metastasis or local disease
  • Prior hormone treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Arizona Cancer Center

Tucson, Arizona, 85724, United States

Location

UCLA

Los Angeles, California, 90095, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 21, 2002

First Posted

June 25, 2002

Study Start

May 1, 2002

Last Updated

November 2, 2006

Record last verified: 2006-10

Locations

US(3)